samedan logo

 
 
spacer
home > ebr > spring 2019 > opportunities and challenges in cancer innovations
PUBLICATIONS
European Biopharmaceutical Review

Opportunities and Challenges in Cancer Innovations

Progress is being made in the long-standing battle to effectively treat and control cancer. The National Cancer Institute projects that nearly five million more US citizens are expected to survive cancer in 2026 than in 2016 (1). Therapeutic tools like nextgeneration sequencing and advances in immunotherapy are just two ways that fundamental scientific breakthroughs and innovative thinking are moving the potential for cancer treatment forward.

One of the most revolutionary breakthroughs in this new era is cell and gene therapy. At its most basic definition, gene therapy (also called human gene transfer) is the therapeutic delivery of nucleic acid into a patient’s cells as a drug to treat disease. According to The Journal of Gene Medicine, somewhere around 2,600 gene therapy clinical trials have been undertaken in 38 countries around the world as of November 2017 (2).

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Ger Brophy is Executive Vice President of Biopharma Production at Avantor. In his current role, he is responsible for developing and implementing the company’s biopharma production and supporting the current and future needs of customers. Prior to joining Avantor, Ger held a variety of R&D, strategy, advanced systems, and business development positions in the healthcare space with GE Healthcare Life Sciences, GE Healthcare Medical Diagnostics, and Amersham for nearly 30 years. He earned a BSc in biotechnology as well as a PhD in molecular biology from Dublin City University, Ireland.
spacer
Dr Ger Brophy
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Northway Biotechpharma and Hansa Biopharma initiate a new Contract Development and Manufacturing project in immunological diseases

Vilnius, Lithuania, and Lund, Sweden - December 20th, 2019 – Northway Biotechpharma, a leading biopharmaceutical Contract Development and Manufacturing Organization (CDMO), and Hansa Biopharma, the leader in immunomodulatory enzyme technology for rare IgG-mediated diseases, today announced a new service agreement to develop the next generation of IgG cleaving enzymes.
More info >>

White Papers

Novo Nordisk Pharmatech A/S signs distribution agreement with DKSH for twelve countries in Asia Pacific.

Novo Nordisk Pharmatech A/S

Novo Nordisk Pharmatech A/S and DKSH, have partnered to provide high-quality cGMP quaternary ammonium compounds in twelve countries across Asia Pacific.
More info >>

 
Industry Events

2020 Avoca Quality and Innovation Summit

3-4 June 2020, Amsterdam, The Netherlands

The 2020 Avoca Quality and Innovation Summit will take place 3-4 June 2020, in Amsterdam, The Netherlands.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement